Seattle Genetics releases more promising brentuximab data; Oxigene trial demonstrates spike in thyroid cancer survival rate;

 @FierceBiotech: Boehringer stops female libido drug program. Article | Follow @FierceBiotech

 @JohnCFierce: Happy to see Mario Vargas Llosa win the Nobel this week. Can't remember the last time they gave it to someone whose work I know. |  Follow @JohnCFierce

> Seattle Genetics has released another promising set of data for brentuximab, or SGN-35. The developer said that 86 percent of patients with advanced systemic anaplastic large cell lymphoma responded to treatment in a Phase II study. Just last month Seattle Genetics released positive data from a study on advanced Hodgkin's disease. Story

> Oxigene reports that a new trial of Zybrestat demonstrated a one-month boost in survival time for thyroid cancer patients. And researchers said that close to half of the patients in the drug/chemo arm were alive at six months, compared with 37 percent of the patients receiving only chemotherapy. Report

> NanoInk has closed a $65 million financing led by Lurie Investments. NanoInk specializes in nanometer-scale manufacturing and apps development for the life sciences and other industries. NanoInk release

> Auxilium has launched a late-stage study of Xiaflex as a treatment for abnormal curvature of the penis. The drug is already approved as a treatment for Dupuytren's contracture, which causes fingers to curl in. Story

And Finally... Researchers at The University of Western Ontario have discovered there is a causal link between enhanced visual abilities and a reorganization of the part of the brain that handles auditory input in congenitally deaf cats. Release

Suggested Articles

Almirall is pulling the trigger on an option to advance Dermira's lebrikizumab in Europe, a program it reckons could rake in €450 million.

Acer Therapeutics’ stock plummeted more than 78% premarket this morning on news that the FDA had rejected approval of its drug Edsivo (celiprolol).

The latest setback prompted Novartis-partnered Conatus to lay off 40% of its staff and begin looking for strategic alternatives.